8-K: Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

Rhythm Pharmaceuticals has secured a $150 million investment through the sale of convertible preferred stock to fund its operations into 2026.

Summary

• Rhythm Pharmaceuticals has entered into an investment agreement to sell $150 million of its Series A convertible preferred stock.
• The investors are led by Perceptive Advisors LLC and include a life-sciences focused institutional investor.
• The proceeds will be used to fund clinical development programs, commercialization activities, working capital, and general corporate purposes.
• The transaction is expected to close around April 15, 2024, subject to customary closing conditions.
• The company expects its existing cash, cash equivalents, short-term investments, and the net proceeds from this sale will fund operations into 2026.
• The preferred stock will be convertible into common stock at an initial rate of 20.8333 shares per $1,000 of liquidation preference, implying a $48 conversion price.
• This conversion price represents a 19% premium to the company's 10-day trailing volume weighted average price.
• The conversion rate is subject to customary adjustments and adjustments for certain dilutive issuances.
• Rhythm can force conversion if the common stock price exceeds 250% of the conversion price for 20 of 30 trading days.
• The company can redeem the preferred stock at the liquidation preference after five years.
• Holders will receive a 6% cumulative annual dividend starting on the second anniversary of closing, compounded quarterly, payable in cash or in kind at the company's option.
• The preferred stock will vote with common stock on an as-converted basis after certain antitrust conditions are met.
• Holders are entitled to 175% of the liquidation preference upon certain corporate events, including a change of control or liquidation.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful capital raise, which is expected to fund operations into 2026. The terms of the financing, including the premium on the conversion price and the dividend, are also favorable. However, there are some risks and potential negatives associated with the preferred stock structure.

Positives

• The $150 million financing provides a significant capital injection for Rhythm Pharmaceuticals.
• The company has secured funding to execute its corporate strategy through multiple value-creating milestones.
• The cash runway extends well beyond the anticipated topline data readout from the phase 3 trial in hypothalamic obesity in the first half of 2025.
• The conversion price of $48 per share represents a 19% premium to the 10-day trailing volume weighted average price.
• The 6% cumulative annual dividend, starting on the second anniversary of closing, provides a return for investors.

Negatives

• The preferred stock ranks senior to common stock in terms of dividends and liquidation, which could be seen as a negative for common shareholders.
• The company has the option to pay dividends in kind, which could dilute common shareholders if paid in stock.
• The company can force conversion of the preferred stock if the common stock price exceeds 250% of the conversion price, which could limit upside for preferred shareholders.

Risks

• The closing of the transaction is subject to customary closing conditions, which could delay or prevent the financing.
• The company's ability to execute its corporate strategy and achieve milestones is subject to various risks and uncertainties.
• The company's ability to successfully commercialize setmelanotide and other pipeline assets is subject to regulatory and market risks.
• The company's future financial performance is subject to various risks and uncertainties, including competition and general economic conditions.

Future Outlook

The company expects the net proceeds from the sale of Preferred Stock, in addition to its cash, cash equivalents and short-term investments as of December 31, 2023, will be sufficient to fund its operating expenses and capital expenditure requirements into 2026.

Management Comments

• We are pleased to announce this convertible preferred stock offering, led by Perceptive Advisors and its Discovery Fund, and we are pleased to receive continued support from a second, existing shareholder who chose to participate in this financing, said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm.
• This financing is expected to provide the capital we need to execute our corporate strategy through multiple potentially value-creating milestones, with sufficient cash runway well beyond our anticipated topline data readout from our phase 3 trial in hypothalamic obesity in the first half of 2025.
• Rhythm with its lead asset IMCIVREE (setmelanotide) approved and available in 14 countries, including the United States, to treat certain rare melanocortin-4 receptor diseases has executed very well against its development, regulatory and commercial strategies on a global level, said Konstantin Poukalov, Managing Director and Perceptive Discovery Co-Head.
• We believe the Company has a clear and achievable global vision to address the unmet needs in additional rare MC4R pathway diseases, including hypothalamic obesity, with setmelanotide and its additional pipeline assets.

Industry Context

This financing reflects continued investor interest in the biopharmaceutical sector, particularly in companies focused on rare diseases. The participation of Perceptive Advisors, a well-known healthcare investor, signals confidence in Rhythm's strategy and pipeline. The focus on funding clinical development and commercialization activities aligns with the industry's emphasis on bringing innovative therapies to market.

Comparison to Industry Standards

• The convertible preferred stock structure is a common financing method for biotech companies, allowing them to raise capital without immediate dilution of common stock.
• The 19% premium on the conversion price is a positive signal for investors, indicating a belief in the company's future growth.
• The 6% cumulative annual dividend is relatively standard for preferred stock offerings in the biotech sector.
• The 175% liquidation preference upon a change of control is a protective measure for preferred shareholders, common in similar deals.
• Comparable companies that have used similar financing structures include companies like BioMarin Pharmaceutical Inc. and Sarepta Therapeutics Inc., which have also raised capital through convertible preferred stock offerings to fund their clinical development and commercialization efforts.

Stakeholder Impact

• Shareholders: The financing provides capital for the company's growth, but the preferred stock structure may dilute common shareholders.
• Employees: The financing provides job security and resources for the company's operations.
• Customers: The financing supports the development and commercialization of new therapies for patients with rare neuroendocrine diseases.
• Creditors: The financing improves the company's financial stability and reduces the risk of default.
• Suppliers: The financing ensures the company's ability to pay for goods and services.

Next Steps

• The transaction is expected to close on or about April 15, 2024, subject to customary closing conditions.
• The company will use the proceeds to fund its clinical development programs and commercialization activities.
• The company will continue to advance its pipeline assets, including setmelanotide and other investigational MC4R agonists.

Key Dates

Keywords

convertible preferred stock, financing, capital raise, biopharmaceutical, rare neuroendocrine diseases, setmelanotide, IMCIVREE, clinical development, commercialization, Perceptive Advisors